Preliminary phase II results of the CYPIDES study of ODM208 in metastatic castration-resistant prostate (mCRPC) cancer patients

被引：0
|
作者：
Fizazi, K. [1 ]
Bernard-Tessier, A. [1 ]
Barthelemy, P. [2 ]
Utriainen, T. [3 ]
Roubaud, G. [4 ]
Flechon, A. [5 ]
van der Voet, J. C. M. [6 ]
Mescam, G. Gravis [7 ]
Ratta, R. [8 ]
Jones, R. H. [9 ]
Parikh, O. A. [10 ]
Tanner, M. M. E. [11 ]
Garratt, C. [12 ]
Nevalaita, L. [13 ]
Pohjanjousi, P. [13 ]
Ikonen, T. [13 ]
Antonarakis, E. S. [14 ]
Cook, N. [15 ]
机构：
[1] Inst Gustave Roussy, Med Oncol, Villejuif, France
[2] ICANS Inst Cancerol, Med Oncol, Strasbourg, France
[3] Univ Helsinki, Oncol, Cent Hosp, Helsinki, Finland
[4] Inst Bergonie, Med Oncol, Bordeaux, France
[5] Ctr Leon Berard, Med Oncol, Lyon, France
[6] James Cook Univ Hosp, Radiotherapy, Middlesbrough, Cleveland, England
[7] IPC Inst Paoli Calmettes, Med Oncol, Marseille, France
[8] Hop Foch, Med Oncol, Suresnes, France
[9] NHS Wales, Velindre Canc Ctr, Cardiff, Wales
[10] Lancashire Teaching Hosp NHS Fdn Trust, Royal Preston Hosp, Oncol, Preston, Lancs, England
[11] Tampere Univ Hosp Tays, R&D, Tampere, Finland
[12] Orion Corp Orion Pharma, R&D, Newbury NG1 1AH, Berks, England
[13] Orion Corp Orion Pharma, R&D, Espoo, Finland
[14] Johns Hopkins Univ, Med Oncol, Baltimore, MD USA
[15] Christie NHS Fdn Trust, Med Oncol, Manchester, Lancs, England
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1364MO
引用
收藏
页码：S1165 / S1165
页数：1
相关论文
共 50 条
  • [1] Preliminary phase 2 results of the CYPIDES study of ODM-208 in metastatic castration-resistant prostate cancer patients
    Cook, Natalie
    Bernard-Tessier, Alice
    Barthelemy, Philippe
    Utriainen, Tapio
    Roubaud, Guilhem
    Flechon, Aude
    van der Voet, Hans
    Gravis Mescam, Gwenaelle
    Ratta, Raffaele
    Jones, Rob
    Parikh, Omi
    Tanner, Minna
    Garratt, Chris
    Nevalaita, Liina
    Pohjanjousi, Pasi
    Ikonen, Tarja
    Antonarakis, Emmanuel
    Fizazi, Karim
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2023, 19 : 87 - 88
  • [2] Phase II Study with metastatic castration-resistant Prostate Cancer (mCRPC) Patients
    Rexer, H.
    Graefen, M.
    UROLOGE, 2017, 56 (11): : 1468 - 1470
  • [3] Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
    Fizazi, K.
    Roubaud, G.
    Bernard-Tessier, A.
    Gravis, G.
    Flechon, A.
    Ratta, R.
    Barthelemy, P.
    Jones, R. J.
    Parikh, O. A.
    Hussain, A.
    van der Voet, J. C. M.
    Cook, N.
    Tanner, M. M. E.
    Jones, R. H.
    Garratt, C.
    Ikonen, T.
    Pohjanjousi, P.
    Poehlein, C. H.
    Antonarakis, E. S.
    ANNALS OF ONCOLOGY, 2024, 35 : S968 - S968
  • [4] Phase 1 results of the ODM-208 first-in-human phase 1-2 trial in patients with metastatic castration-resistant prostate cancer (CYPIDES).
    Fizazi, Karim
    Cook, Natalie
    Barthelemy, Philippe
    Bernard-Tessier, Alice
    Baldini, Capucine
    Peters, Niamh
    Nykanen, Pirjo
    Ikonen, Tarja
    Pohjanjousi, Pasi
    Mattila, Leena
    Jouhi, Lauri
    Vuorela, Annamari
    Garratt, Chris
    Utriainen, Tapio
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [5] Phase II cohort study in patients with metastatic castration-resistant prostate cancer (mCRPC) with new cohorts
    Rexer, Heidrun
    Retz, Margitta
    Hammerer, Peter
    AKTUELLE UROLOGIE, 2022, 53 (06) : 504 - 505
  • [6] MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations: CYPIDES phase 2 results.
    Fizazi, Karim
    Roubaud, Guilhem
    Bernard-Tessier, Alice
    Gravis, Gwenaelle
    Flechon, Aude
    Ratta, Raffaele
    Barthelemy, Philippe
    Jones, Robert J.
    Parikh, Omi
    Hussain, Arif
    van der Voet, Hans
    Cook, Natalie
    Peters, Niamh
    Tanner, Minna
    Jones, Robert Hugh
    Garratt, Chris
    Pohjanjousi, Pasi
    Ikonen, Tarja
    Poehlein, Christian Heinrich
    Antonarakis, Emmanuel S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 159 - 159
  • [7] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Werner, Lillian
    Erlander, Mark G.
    Ridinger, Maya
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [8] A phase II study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [9] Bone and soft tissue response from a phase I/II study with ODM-201 in metastatic castration-resistant prostate cancer (mCRPC)
    Garcia, Jorge A.
    Kataja, Vesa V.
    James, Nicholas David
    Jones, Robert Hugh
    Protheroe, Andrew
    Massard, Christophe
    Mattila, Leena
    Mustonen, Mika V. J.
    Aspegren, John
    Fizazi, Karim
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [10] Randomized phase II trial of abiraterone ± dasatinib for patients with metastatic castration-resistant prostate cancer (mCRPC).
    Dorff, Tanya B.
    Quinn, David I.
    Pinski, Jacek K.
    Goldkorn, Amir
    Sadeghi, Sarmad
    Tsao-Wei, Denice
    Groshen, Susan G.
    Kuhn, Peter
    Gross, Mitchell E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
12345